Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes

被引：67

作者：

Hartmann, Julia ^{[1
,2
]}

Braulke, Friederike ^{[1
]}

Sinzig, Ursula ^{[1
]}

Wulf, Gerald ^{[1
]}

Maas, Jens Holger ^{[3
]}

Konietschke, Frank ^{[4
]}

Haase, Detlef ^{[1
]}

机构：

[1] Univ Gottingen, Dept Hematol & Oncol, D-37075 Gottingen, Germany

[2] Stadt Klinikum Brandenburg GmbH, Dept Pediat, Brandenburg, Germany

[3] Univ Gottingen, Dept Transfus Med, D-37075 Gottingen, Germany

[4] Univ Gottingen, Dept Med Stat, D-37075 Gottingen, Germany

来源：

LEUKEMIA RESEARCH | 2013年 / 37卷 / 03期

关键词：

Iron overload; Colony forming assays; BFU-E; CFU-GM; Proliferation capacity; Chelation therapy; SCORING SYSTEM; MDS; DEFERASIROX; MANAGEMENT; CHELATION; PROGNOSIS; SURVIVAL; DISEASE; HEALTH;

D O I：

10.1016/j.leukres.2012.11.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

In patients with myelodysplastic syndromes (MDS) iron overload caused by long-term red blood cell transfusions is an important factor for comorbidity especially in low-risk MDS. In this report we present the results of a comparative study based on colony formation assays of hematopoietic cells in MDS patients with and without iron overload. We demonstrate that iron overload suppresses the proliferation of erythroid progenitors cells (BFU-E), while the myeloid compartment (CFU-GM) was not found to be affected. Even patients with slightly elevated ferritin values show an impaired proliferation capacity in comparison to patients with normal ferritin levels. Furthermore, we show that this negative impact is reversible by sufficient iron chelation therapy. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：327 / 332

页数：6

共 27 条

[1]

[Anonymous], CANC MED

[2]

Consensus statement on iron overload in myelodysplastic syndromes [J].

Bennett, John M. .

AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (11) :858-861

[3]

Leukemic cluster growth in culture is an independent risk factor for acute myeloid leukemia and short survival in patients with myelodysplastic syndrome [J].

Bernimoulin, Michael ;

Stern, Martin ;

Tichelli, Andre ;

Jotterand, Martine ;

Gratwohl, Alois ;

Nissen, Catherine .

ACTA HAEMATOLOGICA, 2008, 119 (04) :226-235

[4]

Brechignac S, 2004, BLOOD, V104, p263B

[5]

Cazzola Mario, 2008, Hematology Am Soc Hematol Educ Program, P166, DOI 10.1182/asheducation-2008.1.166

[6]

Myelodysplastic syndromes: From pathogenesis and prognosis to treatment [J].

Fenaux, P .

SEMINARS IN HEMATOLOGY, 2004, 41 (02) :6-12

[7]

Matched-Pair Analysis of 186 MDS Patients Receiving Iron Chelation Therapy or Transfusion Therapy Only. [J].

Fox, Frank ;

Kuendgen, Andrea ;

Nachtkamp, Kathrin ;

Strupp, Corinna ;

Haas, Rainer ;

Germing, Ulrich ;

Gattermann, Norbert .

BLOOD, 2009, 114 (22) :694-694

[8]

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study [J].

Gattermann, Norbert ;

Finelli, Carlo ;

Della Porta, Matteo ;

Fenaux, Pierre ;

Ganser, Arnold ;

Guerci-Bresler, Agnes ;

Schmid, Mathias ;

Taylor, Kerry ;

Vassilieff, Dominique ;

Habr, Dany ;

Domokos, Gabor ;

Roubert, Bernard ;

Rose, Christian .

LEUKEMIA RESEARCH, 2010, 34 (09) :1143-1150

[9]

International scoring system for evaluating prognosis in myelodysplastic syndromes [J].

Greenberg, P ;

Cox, C ;

LeBeau, MM ;

Fenaux, P ;

Morel, P ;

Sanz, G ;

Sanz, M ;

Vallespi, T ;

Hamblin, T ;

Oscier, D ;

Ohyashiki, K ;

Toyama, K ;

Aul, C ;

Mufti, G ;

Bennett, J .

BLOOD, 1997, 89 (06) :2079-2088

[10]

Cytogenetic analysis of CD34(+) subpopulations in AML and MDS characterized by the expression of CD38 and CD117 [J].

Haase, D ;

FeuringBuske, M ;

Schafer, C ;

Schoch, C ;

Troff, C ;

Gahn, B ;

Hiddemann, W ;

Wormann, B .

LEUKEMIA, 1997, 11 (05) :674-679

← 1 2 3 →